Recombinant Human TRAIL/TNFRSF10 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01258P-100UG

Human TRAIL on Tris-Bis PAGE under reduced condition. The purity is greater than 95%.
Recombinant Human TRAIL/TNFRSF10 Protein, Active
Beta LifeScience
SKU/CAT #: BLK-01258P-100UG
Collections: All products, High-quality recombinant proteins
Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.
Product Overview
Description | Recombinant Human TRAIL/TNFRSF10 Protein is expressed from E.coli without tag.It contains Val114-Gly281. |
Purity | > 95% as determined by Tris-Bis PAGE;> 95% as determined by SEC-HPLC |
Accession | NP_003801.1 |
Target Symbol | TRAIL/TNFRSF10 |
Synonyms | Apo-2L; TRAIL; CD253; TNFSF10; Apo-2 ligand; APO2L; TL2 |
Species | Human |
Expression System | E. coli |
Tag | No Tag |
Expression Range | Val114-Gly281 |
Mol. Weight | The protein has a predicted MW of 19.6 kDa same as Tris-Bis PAGE result. |
Form | Liquid |
Formulation | Supplied as 0.22um filtered solution in 50mM Tris, 300mM NaCl (pH 7.2). |
Endotoxin | Less than 1EU per ug by the LAL method. |
Activity | Immobilized Human TRAIL at 2ug/ml (100ul/well) on the plate. Dose response curve for Human TRAIL R1, hFc Tag with the EC50 of 25.4ng/ml determined by ELISA (QC Test). The affinity constant of 0.57 nM as determined in SPR assay (Biacore T200). Contact us for detailed testing images. |
Storage | Valid for 12 months from date of receipt when stored at -80°C.; Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles. |
Shipping | Shipped with dry ice. |
Gene Background | Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a member of the TNF superfamily that can initiate the apoptosis pathway by binding to its associated death receptors DR4 and DR5. The activation of the TRAIL pathway in inducing tumor-selective apoptosis leads to the development of TRAIL-based cancer therapies, which include recombinant forms of TRAIL, TRAIL receptor agonists, and other therapeutic agents. |